DrugPatentWatch Database Preview
TRIESENCE Drug Patent Profile
Email this page to a colleague
When do Triesence patents expire, and when can generic versions of Triesence launch?
Triesence is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-five patent family members in twenty-one countries.
The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Triesence
A generic version of TRIESENCE was approved as triamcinolone acetonide by TARO on October 1st, 1986.
Summary for TRIESENCE
| International Patents: | 25 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Clinical Trials: | 9 |
| Patent Applications: | 4,193 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TRIESENCE |
| What excipients (inactive ingredients) are in TRIESENCE? | TRIESENCE excipients list |
| DailyMed Link: | TRIESENCE at DailyMed |
Recent Clinical Trials for TRIESENCE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Wake Forest University Health Sciences | Phase 4 |
| Duke University | N/A |
| Bausch & Lomb Incorporated | N/A |
Pharmacology for TRIESENCE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for TRIESENCE
US Patents and Regulatory Information for TRIESENCE
TRIESENCE is protected by three US patents.
Patents protecting TRIESENCE
Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: VISUALIZATION DURING VITRECTOMY PROCEDURES
Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: TREATMENT OF OPHTHALMIC DISORDERS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Novartis | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRIESENCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | ⤷ Try it Free | ⤷ Try it Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRIESENCE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101555293 | ⤷ Try it Free |
| Taiwan | I468165 | ⤷ Try it Free |
| Denmark | 2262506 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
